Barely Significant
← all excerpts

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting.

World J Gastrointest Pharmacol Ther · 2018 · PMC5797978 · PMID 29430323

Europe PMCDOI
2
hedged sentences
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

showed a trendP < 0.0001actually significant
The Cochran Armitage test showed a trend towards decreasing CT use for CD overall ( P < 0.0001) and CD induction, ( P = 0.0024).

also in 53,322 other papers

a significant trendno p-value reported
Notably, we observed a significant trend of decreasing use of CT for IBD generally, in the CD cohort, as well as for the subgroup of CD patients receiving induction therapy.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.